%0 Journal Article
%T Hepatitis B Virus (HBV) Infection in Patients at Pasteur Institute of Dakar in Senegal from 2016 to 2020: Prevalence and Seroprotection Level
%A Diop Abdou
%A Ndiaye Babacar
%A Diallo Thierno Abdoulaye
%A Mahou Chantal
%A Gu¨¨ye Omar
%A Dubrous Philippe
%A Dubrous Philippe
%A Seck Abdoulaye
%J Open Journal of Medical Microbiology
%P 68-77
%@ 2165-3380
%D 2023
%I Scientific Research Publishing
%R 10.4236/ojmm.2023.131006
%X <span style=\"font-size:10.0pt;font-family:&quot;\">Hepatitis B virus (HBV) infection is highly endemic
in Senegal. Vaccination of all children against HBV was introduced in 1999 and
included in Expanded Programme on Immunisation in 2005. The aim of this study
was to assess the prevalence and immune status against HBV in patients received
at Pasteur Institut in Dakar, Senegal. <b>Methods:</b> Between January 2016 and
December 2020, patients aged between 1 and 96 years received laboratory were
included in the study. Serum samples were analysed for HBV serology (HBs
antigen: HBsAg, HBs antibody: HBsAb and HBc antibody: HBcAb) using ARCHITECT</span><sup><span style=\"font-size:10.0pt;font-family:&quot;\">?</span></sup><span style=\"font-size:10.0pt;font-family:&quot;\"> analyser. Patients with anti-HBs antibody levels (HBsAb</span><span style=\"font-size:10.0pt;font-family:&quot;\"> </span><span style=\"font-size:10.0pt;font-family:&quot;\">¡Ý</span><span style=\"font-size:10.0pt;font-family:&quot;\"> </span><span style=\"font-size:10.0pt;font-family:&quot;\">10 IU/l) were considered seroprotected against HBV. <b>Results: </b>A
total of 5629 patients were analysed with a mean age of 39 years and extremes
from 1 to 96 years. The most represented age group was 31</span><span style=\"font-size:10.0pt;font-family:&quot;\"> </span><span style=\"font-size:10.0pt;font-family:&quot;\">-</span><span style=\"font-size:10.0pt;font-family:&quot;\"> </span><span style=\"font-size:10.0pt;font-family:&quot;\">45 years with 38.4%. HBsAg was present in 520 patients (9.2%) and was
sign</span><span style=\"font-size:10.0pt;font-family:&quot;\">ed</span><span style=\"font-size:10.0pt;font-family:&quot;\"> by sex and age group. Anti-HBc antibodies were found in 52.7% of
patients and 1603 (28.48%) had isolated anti-HBs antibodies reflecting
proportion of people vaccinated at the time of the study. However, 2143
patients (41.9%) had no seroprotection (HBsAb</span><span style=\"font-size:10.0pt;font-family:&quot;\"> </span><span style=\"font-size:10.0pt;font-family:&quot;\">&lt;</span><span style=\"font-size:10.0pt;font-family:&quot;\"> </span><span style=\"font-size:10.0pt;font-family:&quot;\">10 IU/L) and 640 (12.6%) had strong seroprotection defined as HBsAb</span><span style=\"font-size:10.0pt;font-family:&quot;\"> </span><span style=\"font-size:10.0pt;font-family:&quot;\">&gt;</span><span style=\"font-size:10.0pt;font-family:&quot;\"> </span><span style=\"font-size:10.0pt;font-family:&quot;\">1000 IU/L. <b>Conclusion:</b> Our results show a significant presence of
virus in
%K HBsAb
%K HBsAg
%K HBV
%K Seroprevalence
%K Seroprotection
%K Vaccination
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=123623